Budget impact of Cytisinicline
1 evidence topic · 2 sources
Summary
ICER modeled a five-year U.S. budget impact using a hypothetical $5,000 price for a 12-week course. At that price, 4.3% of the eligible population could be treated without exceeding its $880 million annual budget-impact threshold. The manufacturer had not announced a U.S. price.